222 related articles for article (PubMed ID: 16142997)
1. Genomics in multiple myeloma: biology and clinical implications.
Chng WJ; Fonseca R
Pharmacogenomics; 2005 Sep; 6(6):563-73. PubMed ID: 16142997
[TBL] [Abstract][Full Text] [Related]
2. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients.
Carrasco DR; Tonon G; Huang Y; Zhang Y; Sinha R; Feng B; Stewart JP; Zhan F; Khatry D; Protopopova M; Protopopov A; Sukhdeo K; Hanamura I; Stephens O; Barlogie B; Anderson KC; Chin L; Shaughnessy JD; Brennan C; Depinho RA
Cancer Cell; 2006 Apr; 9(4):313-25. PubMed ID: 16616336
[TBL] [Abstract][Full Text] [Related]
3. [Genetic tools for risk-stratification in multiple myeloma].
Braggio E; Albarracín Garramuño F
Medicina (B Aires); 2013; 73(4):369-75. PubMed ID: 23924539
[TBL] [Abstract][Full Text] [Related]
4. Myeloma: classification and risk assessment.
Fonseca R; Monge J
Semin Oncol; 2013 Oct; 40(5):554-66. PubMed ID: 24135400
[TBL] [Abstract][Full Text] [Related]
5. Myeloma genetics and genomics: practice implications and future directions.
Faiman B
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):436-40. PubMed ID: 25127058
[TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma.
Sawyer JR
Cancer Genet; 2011 Jan; 204(1):3-12. PubMed ID: 21356186
[TBL] [Abstract][Full Text] [Related]
7. High detection rate of clinically relevant genomic abnormalities in plasma cells enriched from patients with multiple myeloma.
Stevens-Kroef M; Weghuis DO; Croockewit S; Derksen L; Hooijer J; Elidrissi-Zaynoun N; Siepman A; Simons A; Kessel AG
Genes Chromosomes Cancer; 2012 Nov; 51(11):997-1006. PubMed ID: 22833442
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling.
Stewart AK; Fonseca R
J Clin Oncol; 2005 Sep; 23(26):6339-44. PubMed ID: 16155017
[TBL] [Abstract][Full Text] [Related]
9. Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings.
Richardson PG; Laubach J; Mitsiades CS; Schlossman R; Hideshima T; Redman K; Chauhan D; Ghobrial IM; Munshi N; Anderson KC
Br J Haematol; 2011 Sep; 154(6):755-62. PubMed ID: 21732930
[TBL] [Abstract][Full Text] [Related]
10. Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma.
Dutta AK; Hewett DR; Fink JL; Grady JP; Zannettino ACW
Br J Haematol; 2017 Jul; 178(2):196-208. PubMed ID: 28466550
[TBL] [Abstract][Full Text] [Related]
11. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
12. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.
Neben K; Jauch A; Bertsch U; Heiss C; Hielscher T; Seckinger A; Mors T; Müller NZ; Hillengass J; Raab MS; Ho AD; Hose D; Goldschmidt H
Haematologica; 2010 Jul; 95(7):1150-7. PubMed ID: 20220069
[TBL] [Abstract][Full Text] [Related]
13. Clinical use of genomics in multiple myeloma.
Shaughnessy JD
Clin Adv Hematol Oncol; 2006 Jun; 4(6):419-21. PubMed ID: 16981662
[No Abstract] [Full Text] [Related]
14. Multiple Myeloma Genomics - A Concise Review.
Castaneda O; Baz R
Acta Med Acad; 2019 Apr; 48(1):57-67. PubMed ID: 31264433
[TBL] [Abstract][Full Text] [Related]
15. Optimising patient outcomes in myeloma.
Harousseau JL
Cancer Treat Rev; 2010 May; 36 Suppl 2():S33-5. PubMed ID: 20472187
[TBL] [Abstract][Full Text] [Related]
16. [Genetic markers as prognostic factors in multiple myeloma].
Conte L G; Braggio E; Figueroa G; Fonseca R
Rev Med Chil; 2009 Apr; 137(4):552-8. PubMed ID: 19623423
[TBL] [Abstract][Full Text] [Related]
17. Genomic heterogeneity in multiple myeloma.
Szalat R; Munshi NC
Curr Opin Genet Dev; 2015 Feb; 30():56-65. PubMed ID: 25982873
[TBL] [Abstract][Full Text] [Related]
18. Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.
Shaughnessy JD; Haessler J; van Rhee F; Anaissie E; Pineda-Roman M; Cottler-Fox M; Hollmig K; Zangari M; Mohiuddin A; Alsayed Y; Grazziutti M; Epstein J; Crowley J; Barlogie B
Br J Haematol; 2007 Jun; 137(6):530-6. PubMed ID: 17489983
[TBL] [Abstract][Full Text] [Related]
19. Clinical roundtable monograph. Emerging treatment options for relapsed and refractory multiple myeloma.
Siegel DS; Vij R; Jakubowiak AJ
Clin Adv Hematol Oncol; 2011 Apr; 9(4):1-15. PubMed ID: 21928467
[TBL] [Abstract][Full Text] [Related]
20. Oligonucleotide-based array CGH as a diagnostic tool in multiple myeloma patients.
Smetana J; Fröhlich J; Vranová V; Mikulásová A; Kuglik P; Hájek R
Klin Onkol; 2011; 24 Suppl():S43-8. PubMed ID: 21923064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
